Sathgen Therapeutics
Mumbai, India· Est.
Innovative plant‑derived oncology and antiviral drug developer with a Phase I lead candidate.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative plant‑derived oncology and antiviral drug developer with a Phase I lead candidate.
OncologyAntiviral
Technology Platform
Plant‑derived small‑molecule discovery (MSP series) combined with extensive SAR optimization to target cancer stem cells, enhance chemotherapy, and inhibit viral replication.
Opportunities
Expansion of the MSP platform into additional oncology indications and antiviral indications, plus strategic out‑licensing and co‑development partnerships to accelerate global commercialization.
Risk Factors
Clinical trial attrition, reliance on external financing, and regulatory hurdles could delay progression to later‑stage development.
Competitive Landscape
Competes with other oncology biotech firms developing novel small‑molecule and stem‑cell targeting agents (e.g., ImmunoGen, Nektar), but differentiates via its plant‑derived MSP chemistry and dual oncology/antiviral focus.